bemcentinib | TNBC

Breast cancer is the most common cancer in women

It is estimated that more than 250,000 new cases will be diagnosed in the US in 2018. 20% of breast cancers lack receptors for three common hormones (oestrogen, progesterone and HER2) and are thus called triple-negative breast cancers (TNBC).

Treatment options for TNBC are limited to intense chemotherapy, but disease recurrence is frequent and aggressive. Consequently, novel treatment strategies for TNBC are urgently needed.

Selective AXL inhibition shows promise for the treatment of TNBC

Pre-clinical and translational evidence suggest that AXL inhibition may be synergistic with immune checkpoint blockade.

High AXL expression is a negative prognostic factor in TNBC

Bemcentinib is a selective AXL inhibitor in phase II clinical testing taken orally once a day

Phase II clinical trial of bemcentinib in combination with KEYTRUDA in Patients With TNBC

BGBC007 is a phase II multi-centre open label study of bemcentinib (BGB324) in combination with KEYTRUDA in patients with previously treated, non-resectable TNBC or triple negative inflammatory breast cancer. Up to 56 patients will be included in the study.

Scientific poster presentations

Primary Sidebar

News Subscription

Please remember to confirm your email by clicking on the link provided in the subscription confirmation email.

We will save your name and email address with the sole purpose of sending information regarding our latest news and events. By subscribing to BerGenBio’s newsletter you consent to our Privacy Policy and Terms of Use.